We were fortunate to have an opportunity to speak with MDS Congress Local Organizing Committee member, Philippe Damier (Centre Hospitalier Universitaire Nantes 2INSERM, Hôpital Laennec, Nantes, France). He discussed dyskinesia in Parkinson’s disease, the topic of the plenary session he chaired.
1. How common are dyskinesias in Parkinson’s disease (PD) patients and what are their impact on activities of daily living? (0:05)
2. What is known about the role of glutamate and serotonin receptors on dopamine signalling in dyskinesias? (0:48)
3. How do changes in dendritic spines affect the development of dyskinesias? (2:33)
4. What have been the most important recent advances in the management of dyskinesias in PD? (3:22)
5. What are the key take home messages of your session? (4:24)
Speaker disclosure: Philippe Damier has nothing relevant to disclose in relation to this video interview.
Filmed at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), Nice, France, September 2019.
Share this Video
Related Videos In Parkinson's Disease
Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]
Heinz Reichmann, EAN 2021: Levodopa-based Drugs in the Treatment of Parkinson’s Disease
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]
Stephen Pasternak, AD/PD 2021: Phase 2 trial Investigating Ambroxol as a Treatment for Parkinson’s Disease Dementia
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!